TAK 935

Drug Profile

TAK 935

Alternative Names: OV-935; TAK935

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer Ovid Therapeutics; Takeda
  • Class Antiepileptic drugs; Heterocyclic compounds; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Cholesterol 24-hydroxylase inhibitors; NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dravet syndrome; Lennox-Gastaut syndrome; Tuberous sclerosis
  • Phase I Epilepsy

Most Recent Events

  • 05 Dec 2017 TAK 935 receives Orphan Drug status for Dravet syndrome in USA
  • 05 Dec 2017 Pharmacodynamics data from preclinical trials in Epilepsy released by Ovid Therapeutics
  • 03 Dec 2017 Adverse events and pharmacodynamics data from two phase I trials in healthy volunteers released by Ovid Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top